IgA Saliva

Key Features and Values

– Same sample type can be used across all assays to simplify inclusion into routine serology work-up
– Ready to use reagents reduces hands-on time for assay preparation
– Long shelf life provides a cost-effective solution by reducing wastage due to expired kits
– Suitable for inclusion on automated plate systems simplifies scale-up of test volume
– Supported by a complete panel of assays for supporting treatment monitoring of several forms of hormonal dysfunctions
– Suitable for use in a wide range of areas including sports medicine, paediatrics, occupational health, veterinary medicine, sleep disturbance, stress monitoring and hormone replacement therapy

Product Description

Immunoenzymatic colorimetric method for the quantitative determination of IgA in saliva. IgA Saliva ELISA kit is intended for laboratory use only.

Scientific Description
IgA represents about 15% to 20% of immunoglobulins in the blood, they are also found in the mucus secreted in the stomach, lungs and intestines.  This prevents the microbes to bind to epithelial cells of the respiratory and digestive tract.  This immunoglobulin helps to fight against pathogens that contact the body surface, are ingested, or are inhaled.  It exists in two forms, IgA1 (90%) and IgA2 (10%) that differ in the structure.  IgA1 is found in serum and made by bone marrow B cells, however IgA2 is made by B cells located in the mucosae and has been found to secrete into, colostrum, maternal milk, tears and saliva.
The IgA found in secretions have a special form.  They are dimeric molecules, linked by two additional chains.  One of these is the J chain (from join), which is a polypeptide of molecular mass 1,5 kD, rich with cysteine and structurally completely different from other immunoglobulin chains.  The dimeric form of IgA in the outer secretions also has a polypeptide of the same molecular mass (1,5 kD) called the secretory chain and is produced by epithelial cells.
Decreased or absent IgA, termed selective IgA deficiency, can be a clinically significant immunodeficiency.

1. Tomasi, T.B. Jr. Englewood Cliffs, NJ: Prentice-Hall. (1976)
2. Ben-Aryeh H., et al Archive of Oral Biol. 35, 929-931 (1990)
3. Smith D.J., et al J. Dental Research 66, 451-456 (1987)
4. Ventura M.T.et al Allergol Immunopath (madr) 19, 183-185 (1991)
5. Kugler J., et al J. Clin. Immunol. 12, 45-49 (1992)
6. Jemmott III J.B.et al Behavioral Medicine, 15, 63-71 (1989)
7. Gregory R.I., et al J. Period. Research, 27, 176-183 (1992)
8. Ruan M.S., Chung-Hua-Kou-Chiang-Hsueh-Tsa-Chin, 25, 158-160 (1990)
9. Jemmot III J.B., et al J. Personality and Social Psychology 55, 803-810 (1988)
10. Kugler J.A review. Psychotherapy, Psychosomatic Medicine and Psychology, 41, 232-242 (1991)
11. Shirtcliff E.A., et al Psychoneuroendocrinology, 26, 165-173 (2001)
12. Chard T. An introduction to radioimmunoassay and related techniques

Please enter your email address to download the DKO078-IgA-Saliva-IFU.pdf
Code: DKO078
Clinical Area:
Incubation: 60+15 min
Classification: RUO
Number of Tests: 96
Sample Type: Saliva
Sample Volume: 50 μL
Assay Range: 0.5 - 400 µg/mL